

The Dependable **Trio**



# ESOGRESS-HP

Combipack of Clarithromycin 500 mg, Esomeprazole 40 mg  
and Amoxicillin 750 mg Tablets


# ESOGRESS-HP

Combipack of Clarithromycin 500 mg, Esomeprazole 40 mg  
and Amoxicillin 750 mg Tablets

## BACKGROUND:

- Helicobacter pylori (H. pylori) is probably the most common bacterial infection, with a worldwide prevalence of approximately 50% and 49.94-83.30% high prevalence rate in India<sup>1</sup>. H. pylori is implicated in the etiology of gastritis and peptic ulcers in humans.
- As the eradication of HP infection plays a prime role in reducing the potential risk of complications. Newer triple therapies, including proton-pump inhibitors (PPIs) such as esomeprazole, amoxicillin, and clarithromycin, serve as a shorter, simpler and more effective drug regimen for the eradication of H. pylori.

## NATURAL HISTORY OF HELICOBACTER PYLORI (H. PYLORI) INFECTION<sup>2</sup>:



COMPARISON BETWEEN SINGLE-DOSE ESOMEPRAZOLE AND PANTOPRAZOLE BASED TRIPLE THERAPY ON THE EFFECTIVENESS FOR HELICOBACTER PYLORI ERADICATION IN TAIWANESE POPULATION.<sup>3</sup>


## OUTCOMES OF ESOMEPRAZOLE AND PANTOPRAZOLE BASED TRIPLE THERAPY:

ERADICATION RATE	EAC GROUP (n = 208)	PAC GROUP (n = 245)	P VALUE
Intention-to-treat	72% (150/208)	55% (135/245)	<.05
Per-protocol	91% (150/165)	72% (135/187)	<.05
Compliance	87% (181/208)	91% (223/245)	.083

The eradication rate in the EAC group was significantly better than the PAC group in both the intention to treat (IIT) and per protocol (PP) analyses.

\*EAC: ESOMEPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN \*PAC: PANTOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

## ERADICATION RATE BY TYPES OF TRIPLE THERAPY<sup>4</sup>:



The eradication rate was 63.5% in the amoxicillin, PPI, clarithromycin regimen, 42.9% in the amoxicillin, PPI, metronidazole regimen and 0% in the clarithromycin, PPI, metronidazole regimen. Regimens including amoxicillin showed better eradication rates.

## BENEFITS OF EAC THERAPY:

- PPI-based triple therapy has better tolerability and higher efficacy.
- Esomeprazole 40 mg B.D. improves the H. pylori eradication rate of triple therapy closer to 100%.<sup>5</sup>
- Prolonging the period of PPI-clarithromycin-containing triple treatment from 7 to 14 days increases the eradication rate by about 5%.<sup>6</sup>
- Clarithromycin 500 mg gives a significantly higher eradication rate than the 250 mg dosage.<sup>7</sup>

The Dependable **Trio**



# ESOGRESS-HP

Combipack of Clarithromycin 500 mg, Esomeprazole 40 mg  
and Amoxicillin 750 mg Tablets

## DESCRIPTION:

**ESOGRESS-HP** is a combination of two antibiotics and PPI that effectively treats peptic ulcer disease caused due to *H. pylori* bacterial infection.

**ESOGRESS-HP** contains two tablets of clarithromycin (500 mg), two tablets of esomeprazole (40 mg), and two tablets of amoxicillin (750 mg).

## INDICATION:

For healing of duodenal ulcer associated with *Helicobacter pylori* and eradication of *Helicobacter pylori* in patients with active or healed peptic ulcer.

## MECHANISM OF ACTION:

- Clarithromycin is an antibiotic that works by killing the bacteria (*Helicobacter pylori*) that is causing the infection. Esomeprazole is a proton pump inhibitor and acts by reducing the production of stomach acid.
- Amoxicillin is an antibiotic which works by preventing the formation of the bacterial protective covering which is essential for the survival of bacteria in the human body.
- **ESOGRESS-HP** fights against the bacteria to treat the infection. It also relieves acidity and discomfort related to the infection.

## DOSAGE:

One pack of **ESOGRESS-HP** is for 1 day of treatment. From this specially designed pack, one tablet of clarithromycin, one tablet of esomeprazole, and one tablet of amoxicillin are to be taken in the morning and similarly one each in the evening or as directed by the Physician.

## PRESENTATION:

**ESOGRESS-HP** is a combipack and each pack contains two tablets of clarithromycin, two tablets of esomeprazole, and two tablets of amoxicillin.




### References:

1. Misra V et al. *H. pylori* and gastric cancer
2. INTERNATIONAL JOURNAL OF ONCOLOGY 42: 5-18, 2013
3. Gastroenterology Research and Practice Volume 2012
4. Int Clin Med, 2018 doi: 10.15761/ICM.1000129 Volume 2(3): 1-5
5. Aliment Pharmacol Ther 2005; 21: 283-288
6. World J Gastroenterol 2014 October 28; 20(40): 14527-14536
7. Aliment Pharmacol Ther 13, 719-729



## La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,  
S.G. Highway, Ahmedabad-380015, Gujarat, India.  
Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998  
E-mail: info@larenon.com | Web: www.larenon.com

 I am: \_\_\_\_\_  
 Call me on: \_\_\_\_\_  
 Mail me at: \_\_\_\_\_

©2022 All rights reserved, La Renon Healthcare Private Limited